{"id":63062,"date":"2026-05-06T04:02:26","date_gmt":"2026-05-06T02:02:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/"},"modified":"2026-05-06T04:02:26","modified_gmt":"2026-05-06T02:02:26","slug":"moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/","title":{"rendered":"Moody’s Reaffirmed Afya’s AAA.br Rating With a Stable Outlook"},"content":{"rendered":"
\n

BELO HORIZONTE, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA; B3: A2FY34) (\u201cAfya\u201d or the \u201cCompany<\/b>\u201d)<\/b>, the leading medical education group and medical practice solutions provider in Brazil, announced today that Moody\u2019s reaffirmed Afya\u2019s credit rating at AAA.br and maintained a stable outlook.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe reaffirmation of Afya\u2019s AAA.br rating and stable outlook reflects revenue growth, a track record of above-industry-average margins, very strong credit metrics, exceptional cash generation, and robust liquidity. In addition, Afya\u2019s credit profile reflects a strong competitive position and a predictable financial policy, including proactive liability management and prudent capital allocation, despite its appetite for M&As.<\/p>\n

\nThe Company believes this development further validates the business model and its continued ability to deliver on its long-term strategy with consistency and financial discipline.<\/p>\n

\nAbout Afya Limited (Nasdaq: AFYA, B3: A2FY34)<\/b><\/p>\n

\nAfya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering medical practice solutions to help doctors enhance their healthcare services through their whole career.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations Contact:
\n
Afya Limited
\n
ir@afya.com.br<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BELO HORIZONTE, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA; B3: A2FY34) (\u201cAfya\u201d or the \u201cCompany\u201d), the leading medical education group and medical practice solutions provider in Brazil, announced today that Moody\u2019s reaffirmed Afya\u2019s credit rating at AAA.br and maintained a stable outlook. The reaffirmation of Afya\u2019s AAA.br rating and stable outlook reflects revenue growth, a track record … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-63062","6":"format-standard","7":"category-industry"},"yoast_head":"\nMoody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BELO HORIZONTE, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA; B3: A2FY34) (\u201cAfya\u201d or the \u201cCompany\u201d), the leading medical education group and medical practice solutions provider in Brazil, announced today that Moody\u2019s reaffirmed Afya\u2019s credit rating at AAA.br and maintained a stable outlook. The reaffirmation of Afya\u2019s AAA.br rating and stable outlook reflects revenue growth, a track record ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T02:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260505442587\/en\/1927844\/22\/AF-LOGO-AFYA-POSITIVO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Moody’s Reaffirmed Afya’s AAA.br Rating With a Stable Outlook\",\"datePublished\":\"2026-05-06T02:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/\"},\"wordCount\":235,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260505442587\\\/en\\\/1927844\\\/22\\\/AF-LOGO-AFYA-POSITIVO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/\",\"name\":\"Moody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260505442587\\\/en\\\/1927844\\\/22\\\/AF-LOGO-AFYA-POSITIVO.jpg\",\"datePublished\":\"2026-05-06T02:02:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260505442587\\\/en\\\/1927844\\\/22\\\/AF-LOGO-AFYA-POSITIVO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260505442587\\\/en\\\/1927844\\\/22\\\/AF-LOGO-AFYA-POSITIVO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moody’s Reaffirmed Afya’s AAA.br Rating With a Stable Outlook\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/","og_locale":"en_US","og_type":"article","og_title":"Moody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook - Pharma Trend","og_description":"BELO HORIZONTE, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA; B3: A2FY34) (\u201cAfya\u201d or the \u201cCompany\u201d), the leading medical education group and medical practice solutions provider in Brazil, announced today that Moody\u2019s reaffirmed Afya\u2019s credit rating at AAA.br and maintained a stable outlook. The reaffirmation of Afya\u2019s AAA.br rating and stable outlook reflects revenue growth, a track record ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/","og_site_name":"Pharma Trend","article_published_time":"2026-05-06T02:02:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260505442587\/en\/1927844\/22\/AF-LOGO-AFYA-POSITIVO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Moody’s Reaffirmed Afya’s AAA.br Rating With a Stable Outlook","datePublished":"2026-05-06T02:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/"},"wordCount":235,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260505442587\/en\/1927844\/22\/AF-LOGO-AFYA-POSITIVO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/","url":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/","name":"Moody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260505442587\/en\/1927844\/22\/AF-LOGO-AFYA-POSITIVO.jpg","datePublished":"2026-05-06T02:02:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260505442587\/en\/1927844\/22\/AF-LOGO-AFYA-POSITIVO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260505442587\/en\/1927844\/22\/AF-LOGO-AFYA-POSITIVO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/moodys-reaffirmed-afyas-aaa-br-rating-with-a-stable-outlook\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Moody’s Reaffirmed Afya’s AAA.br Rating With a Stable Outlook"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63062"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63062\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}